These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 15853480)

  • 1. Butyrylcholinesterase: impact on symptoms and progression of cognitive impairment.
    Tasker A; Perry EK; Ballard CG
    Expert Rev Neurother; 2005 Jan; 5(1):101-6. PubMed ID: 15853480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rivastigmine is a potent inhibitor of acetyl- and butyrylcholinesterase in Alzheimer's plaques and tangles.
    Eskander MF; Nagykery NG; Leung EY; Khelghati B; Geula C
    Brain Res; 2005 Oct; 1060(1-2):144-52. PubMed ID: 16212945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cholinesterase inhibitors proposed for treating dementia in Alzheimer's disease: selectivity toward human brain acetylcholinesterase compared with butyrylcholinesterase.
    Pacheco G; Palacios-Esquivel R; Moss DE
    J Pharmacol Exp Ther; 1995 Aug; 274(2):767-70. PubMed ID: 7636741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic effect of apolipoprotein E epsilon4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer's disease.
    Lane R; Feldman HH; Meyer J; He Y; Ferris SH; Nordberg A; Darreh-Shori T; Soininen H; Pirttilä T; Farlow MR; Sfikas N; Ballard C; Greig NH
    Pharmacogenet Genomics; 2008 Apr; 18(4):289-98. PubMed ID: 18334913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Canine cognitive dysfunction and the cerebellum: acetylcholinesterase reduction, neuronal and glial changes.
    Pugliese M; Gangitano C; Ceccariglia S; Carrasco JL; Del Fà A; Rodríguez MJ; Michetti F; Mascort J; Mahy N
    Brain Res; 2007 Mar; 1139():85-94. PubMed ID: 17292335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensitivity of butyrylcholinesterase knockout mice to (--)-huperzine A and donepezil suggests humans with butyrylcholinesterase deficiency may not tolerate these Alzheimer's disease drugs and indicates butyrylcholinesterase function in neurotransmission.
    Duysen EG; Li B; Darvesh S; Lockridge O
    Toxicology; 2007 Apr; 233(1-3):60-9. PubMed ID: 17194517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential CSF butyrylcholinesterase levels in Alzheimer's disease patients with the ApoE epsilon4 allele, in relation to cognitive function and cerebral glucose metabolism.
    Darreh-Shori T; Brimijoin S; Kadir A; Almkvist O; Nordberg A
    Neurobiol Dis; 2006 Nov; 24(2):326-33. PubMed ID: 16973370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of rivastigmine in the treatment of behavioral disturbances associated with dementia: review of neuropsychiatric impairment in Alzheimer's disease.
    Grossberg GT
    Curr Med Res Opin; 2005 Oct; 21(10):1631-9. PubMed ID: 16238903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beyond symptomatic therapy: a re-examination of acetylcholinesterase inhibitors in Alzheimer's disease.
    Relkin NR
    Expert Rev Neurother; 2007 Jun; 7(6):735-48. PubMed ID: 17561789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cholinergic challenge in Alzheimer patients and mild cognitive impairment differentially affects hippocampal activation--a pharmacological fMRI study.
    Goekoop R; Scheltens P; Barkhof F; Rombouts SA
    Brain; 2006 Jan; 129(Pt 1):141-57. PubMed ID: 16251213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Butyrylcholinesterase, ApoE and Alzheimer's disease in a population from the Canary Islands (Spain).
    Déniz-Naranjo MC; Muñoz-Fernández C; Alemany-Rodríguez MJ; del Carmen Pérez-Vieitez M; Aladro-Benito Y; Irurita-Latasa J; Sánchez-García F
    Neurosci Lett; 2007 Oct; 427(1):34-8. PubMed ID: 17923322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Widely spread butyrylcholinesterase can hydrolyze acetylcholine in the normal and Alzheimer brain.
    Mesulam M; Guillozet A; Shaw P; Quinn B
    Neurobiol Dis; 2002 Feb; 9(1):88-93. PubMed ID: 11848688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rivastigmine for subcortical vascular dementia.
    Román GC
    Expert Rev Neurother; 2005 May; 5(3):309-13. PubMed ID: 15938663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The progression of cognition, psychiatric symptoms, and functional abilities in dementia with Lewy bodies and Alzheimer disease.
    Stavitsky K; Brickman AM; Scarmeas N; Torgan RL; Tang MX; Albert M; Brandt J; Blacker D; Stern Y
    Arch Neurol; 2006 Oct; 63(10):1450-6. PubMed ID: 17030662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rivastigmine for Alzheimer's disease.
    Desai AK; Grossberg GT
    Expert Rev Neurother; 2005 Sep; 5(5):563-80. PubMed ID: 16162080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mild cognitive impairment: an opportunity to identify patients at high risk for progression to Alzheimer's disease.
    Levey A; Lah J; Goldstein F; Steenland K; Bliwise D
    Clin Ther; 2006 Jul; 28(7):991-1001. PubMed ID: 16990077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Excessive hippocampal acetylcholine levels in acetylcholinesterase-deficient mice are moderated by butyrylcholinesterase activity.
    Hartmann J; Kiewert C; Duysen EG; Lockridge O; Greig NH; Klein J
    J Neurochem; 2007 Mar; 100(5):1421-9. PubMed ID: 17212694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential distribution of butyrylcholinesterase and acetylcholinesterase in the human thalamus.
    Darvesh S; Hopkins DA
    J Comp Neurol; 2003 Aug; 463(1):25-43. PubMed ID: 12811800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The distribution of senile plaques and acetylcholinesterase staining in the thalamus in dementia of Alzheimer type].
    Yasuhara O; Nakamura S; Akiguchi I; Kimura J; Kameyama M
    Rinsho Shinkeigaku; 1991 Apr; 31(4):377-82. PubMed ID: 1717194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disease progression in vascular cognitive impairment: cognitive, functional and behavioural outcomes in the Consortium to Investigate Vascular Impairment of Cognition (CIVIC) cohort study.
    Rockwood K; Moorhouse PK; Song X; MacKnight C; Gauthier S; Kertesz A; Montgomery P; Black S; Hogan DB; Guzman A; Bouchard R; Feldman H;
    J Neurol Sci; 2007 Jan; 252(2):106-12. PubMed ID: 17189642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.